DOI QR코드

DOI QR Code

Phase II Study on Dose Escalating Schedule of Paclitaxel Concurrent with Radiotherapy in Treating Patients with Locally Advanced Non-small Cell Lung Cancer

  • Cui, Lin (Department of Oncology, Taizhou Second People's Hospital, the Affiliated Hospital of Yangzhou University) ;
  • Liu, Xing-Xiang (Department of Oncology, Taizhou Second People's Hospital, the Affiliated Hospital of Yangzhou University) ;
  • Jiang, Yong (Department of Oncology, Taizhou Second People's Hospital, the Affiliated Hospital of Yangzhou University) ;
  • Liu, Jian-Jun (Department of Oncology, Taizhou Second People's Hospital, the Affiliated Hospital of Yangzhou University) ;
  • Zhou, Xiang-Rong (Department of Oncology, Taizhou Second People's Hospital, the Affiliated Hospital of Yangzhou University) ;
  • He, Xue-Jun (Department of Oncology, Taizhou Second People's Hospital, the Affiliated Hospital of Yangzhou University) ;
  • Chen, Jue (Department of Oncology, Taizhou Second People's Hospital, the Affiliated Hospital of Yangzhou University) ;
  • Huang, Xin-En (Department of Chemotherapy, Affiliated Jiangsu Cancer Hospital of Nanjing Medical University & Jiangsu Institute of Cancer Research)
  • Published : 2014.02.28

Abstract

Objective: To evaluate clinical efficacy of a dose escalating schedule of paclitaxel concurrent with radiotherapy in treating patients with locally advanced non-small cell lung (NSCLC). Methods: Patients with locally advanced NSCLC were treated with conventional fractionated radiotherapy or three dimensional conformal radiotherapy (3 DCRT), concurrently with a dose escalating schedule of paclitaxel. All patients were divided into three groups, A with paclitaxel $30mg/m^2$, B with paclitaxel $60mg/m^2$ and C with paclitaxel $90mg/m^2$. Paclitaxel was repeated every week for a total of 4 or 6 weeks. Results: Among 109 patients, response rates were 68.8%, 71.1% and 71.8% (p>0.05) for group A (n=32), B (n=38), and C (n=39) respectively. Accordingly, disease control rates were 81.3%, 81.6% and 82.1% (p>0.05). Progression-free survival time was $8.0{\pm}5.0$ months, $11.6{\pm}6.1$ months, and $14.8{\pm}7.9$ months (p<0.05), respectively. Overall survival time was $15.4{\pm}7.6$ months, $18.2{\pm}8.0$ months, and $22.0{\pm}7.6$ months (p<0.05), one-year survival rates were 62.5%, 73.1% and 90.0% (p>0.05) and two-year survival rates were 31.3%, 38.5% and 50.0% (p<0.05). Main side-effects were bone marrow suppression, radiation related esophagitis and gastrointestinal reaction. Conclusion: In treating patients with NSCLC, concurrent chemoradiotherapy with paclitaxel improves early response compared with conventional fractionated radiotherapy or 3 DCRT. The survival rate was improved with the addition of paclitaxel, but there was an increase in adverse reactions when the dose of paclitaxel was increased.

References

  1. Yin HT, Tian QZ, Guan L, et al (2013). In vitro and in vivo evaluation of the antitumor efficiency of resveratrol against lung cancer. Asian Pac J Cancer Prev, 14, 1703-6. https://doi.org/10.7314/APJCP.2013.14.3.1703
  2. Vokes E E, Herndon J E 2nd, Crawford J, et al (2002). Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant Chemoradiotherapy for stage M b non-small cell lung cancer: cancer and leukemia group B study 9431. J Clin Oncol, 20, 4191-8. https://doi.org/10.1200/JCO.2002.03.054
  3. Wang X, Wang , Lu J, et al (2006). Concurrent paclitaxel or/and carboplatin with radiotherapy for stageIIInon-small cell lung cancer. Chin J Rad Oncol, 15, 270-4.
  4. Wu Y, Liao M, Jiang G, et al (2002). Consensus on the diagnosis and treatment of local advanced non-small cell lung cancer. Chin J Oncol, 24, 576.
  5. Zhou JN, Huang XE, Ye Z, et al (2009). Weekly paclitaxel/ docetaxel combined with a platinum in the treatment of advanced non-small cell lung cancer: a study on efficacy, safety and pre-medication. Asian Pac J Cancer Prev, 10, 1147-50.
  6. Zhou X, Cui L, Liu J (2009). Sequential and Concurrent Chemo- Radiotherapy for Middle and Advanced Stage Non-Small Cell Lung Cancer. J Basic Clin Oncol, 22, 132-3.
  7. Lu J, Wang L, Zhou Z, et al (2004). Phase II study on concomitant paclitaxel and radiotherapy for loc ally advanced non-small cell lung cancer[J]. Chin J Rad Oncol, 13, 89-92.
  8. Lara PN Jr, Goldberg Z, Davies A, et a1 (2002). Concurrent chemoradiation strategies in the management of unresectable stage III non-small-cell lung cancer. Clin Lung Cancer, 3, 42-8. https://doi.org/10.3816/CLC.2002.s.013
  9. Liu YC, Zhou SB, Gao F, et al (2013). Chemotherapy and late course three dimensional conformal radiotherapy for treatment of patients with stage III non- small cell lung cancer. Asian Pac J Cancer Prev, 14, 2663-5. https://doi.org/10.7314/APJCP.2013.14.4.2663
  10. Lu B, Ouyang W, Yi F, et al (2004). Concurrent chemotherapy and radiotherapy for advanced non-small-cell lung cancer. Chin J Rad Oncol, 13, 177-9.
  11. Lu YY, Huang XE, Cao J, et al (2013). Phase II study on Javanica oil emulsion injection ($Yadanzi^{(R)}$) combined with chemotherapy in treating patients with advanced lung adenocarcinoma. Asian Pac J Cancer Prev, 14, 4791-4. https://doi.org/10.7314/APJCP.2013.14.8.4791
  12. Ourari-Dhahri B, Ben Slima H, Ben Amar J, et al (2012). Management of non small cell lung cancer. Tunis Med, 90, 847-51.
  13. Salama JK, Vokes EE (2013). New radiotherapy and Chemoradiotherapy approaches for non-small-cell lung cancer. J Clin Oncol, 31, 1029-38. https://doi.org/10.1200/JCO.2012.44.5064
  14. Sculier JP (2013). Nonsmall cell lung cancer. Eur Respir Rev, 22, 33-6. https://doi.org/10.1183/09059180.00007012
  15. Solomon B, Ball DL, Richardson G, et al (2003). Phase I/II study of concurrent twice-weekly paclitaxel and weekly cisplatin with radiation therapy for stage III non-small cell lung cancer. Lung Cancer, 41, 353-61. https://doi.org/10.1016/S0169-5002(03)00235-6
  16. Trotti A, Byhardt R, Stetz J, et al (2000). Common toxicity criteria:version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on chemotherapy. Int J Radiat Oncol Biol Phys, 47, 13-47. https://doi.org/10.1016/S0360-3016(99)00559-3
  17. Curran WJ Jr, Paulus R, Langer CJ, et al (2011). Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst, 103, 1452-60. https://doi.org/10.1093/jnci/djr325
  18. Chen LK, Liang Y, Yang QY, et al (2012). Triplet platinum-based combination sequential chemotherapy improves survival outcome and quality of life of advanced non-small cell lung cancer patients. Asian Pac J Cancer Prev, 13, 1863-7. https://doi.org/10.7314/APJCP.2012.13.5.1863
  19. Chen Y, Pandya K, Keng PP, et al (2001). Schedule-dependent pulsed paclitaxel radio-sensitization for thoracic malignancy. Am J Clin Oncol, 24, 432-7. https://doi.org/10.1097/00000421-200110000-00004
  20. Cufer T, Ovcaricek T, O'Brien ME (2013). Systemic therapy of advanced non-small cell lung cancer: major-developments of the last 5-years. Eur J Cancer, 49, 1216-25. https://doi.org/10.1016/j.ejca.2012.11.021
  21. Demirci E1, Daloglu F, Gundogdu C, et al (2013). Incidence and clinicopathologic features of primary lung cancer: a North-Eastern Anatolia region study in Turkey (2006-2012). Asian Pac J Cancer Prev, 14, 1989-93. https://doi.org/10.7314/APJCP.2013.14.3.1989
  22. Field JK, Oudkerk M, Pedersen JH, et al (2013). Prospects for population screening and diagnosis of lung cancer. Lancet, 382, 732-41. https://doi.org/10.1016/S0140-6736(13)61614-1
  23. Fournel P, Robinet G, Thomas P, et al (2005). Randomized phase III trial of sequential Chemoradiotherapy compared with concurrent Chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienned Oncologie Thoracique-Groupe Francais de Pneumo- Cancerologie NPC 95-01 Study. J Clin Oncol, 23, 5910-7. https://doi.org/10.1200/JCO.2005.03.070
  24. Jemal A, Siegel R, Ward E, et al (2010). Cancer statistics, 2010. CA Cancer J Clin, 60, 277-300. https://doi.org/10.3322/caac.20073
  25. Jiang Y, Cui L, Wu X, et al (2012). Radiosensitizing Effect of Weekly-dose Paclitaxel on Locally Advanced Esophageal Carcinoma. J Basic Clin Oncol, 6, 489-92.
  26. Al-Hashimi MM, Wang XJ (2014). Trend analysis of lung cancer incidence rates in ninawa province, iraq, from 2000 to 2010 - decrease and recent stability. Asian Pac J Cancer Prev, 15, 385-90. https://doi.org/10.7314/APJCP.2014.15.1.385
  27. Andoh H, McNulty NJ, Lewis PJ (2013). Improving accuracy in reporting CT scans of oncology patients: assessing the effect of education and feedback interventions on the application of the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. Acad Radiol, 20, 351-7. https://doi.org/10.1016/j.acra.2012.12.002
  28. Byhardt RW, Scott C, Sause WT, Emami B, et al (1998). Response, toxicity, failure patterns, and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell carcinoma of the lung. Int J Radiat Oncol Biol Phys, 42, 469-78. https://doi.org/10.1016/S0360-3016(98)00251-X

Cited by

  1. Clinical Investigation of Efficacy of Albumin Bound Paclitaxel plus Platinum Compounds as First-line Chemotherapy for Stage III/IV Squamous Non-small Cell Lung Cancer vol.15, pp.17, 2014, https://doi.org/10.7314/APJCP.2014.15.17.7453
  2. v6 and E-cadherin and Lymphatic Metastasis in Non-small Cell Lung Cancer vol.15, pp.5, 2014, https://doi.org/10.7314/APJCP.2014.15.5.2221
  3. Targeted Efficacy of Dihydroartemisinin for Translationally Controlled Protein Expression in a Lung Cancer Model vol.15, pp.6, 2014, https://doi.org/10.7314/APJCP.2014.15.6.2511
  4. Analysis of CEA Expression and EGFR Mutation Status in Non-small Cell Lung Cancers vol.15, pp.8, 2014, https://doi.org/10.7314/APJCP.2014.15.8.3451
  5. Anti-Proliferation Effects and Molecular Mechanisms of Action of Tetramethypyrazine on Human SGC-7901 Gastric Carcinoma Cells vol.15, pp.8, 2014, https://doi.org/10.7314/APJCP.2014.15.8.3581
  6. Clinical Study on Safety and Efficacy of JiSaiXin (Recombinant Human Granulocyte Colony Stimulating Factor Injection Manufactured in China) for Chinese Undergoing Chemotherapy vol.16, pp.1, 2015, https://doi.org/10.7314/APJCP.2015.16.1.299
  7. A Pooled Analysis on Crizotinib in Treating Chinese Patients with EML4-ALK Positive Non-small-cell Lung Cancer vol.16, pp.11, 2015, https://doi.org/10.7314/APJCP.2015.16.11.4797
  8. Human Recombinant Endostatin Combined with Cisplatin Based Doublets in Treating Patients with Advanced NSCLC and Evaluation by CT Perfusion Imaging vol.16, pp.15, 2015, https://doi.org/10.7314/APJCP.2015.16.15.6765
  9. Irinotecan as a Second-line Chemotherapy for Small Cell Lung Cancer: a Systemic Analysis vol.16, pp.5, 2015, https://doi.org/10.7314/APJCP.2015.16.5.1993
  10. Analysis on Early Detection of Lung Cancer by PET/CT Scan vol.16, pp.6, 2015, https://doi.org/10.7314/APJCP.2015.16.6.2215
  11. Expression of TS, RRM1, ERCC1, TUBB3 and STMN1 Genes in Tissues of Non-small Cell Lung Cancer and its Significance in Guiding Postoperative Adjuvant Chemotherapy vol.16, pp.8, 2015, https://doi.org/10.7314/APJCP.2015.16.8.3189
  12. Organ-sparing Surgery in Treating Patients with Liposarcoma of the Spermatic Cord: Institutional Experience and Pooled Analysis vol.16, pp.8, 2015, https://doi.org/10.7314/APJCP.2015.16.8.3419
  13. Radioactive Seed Implantation and Lobaplatin Chemotherapy Are Safe and Effective in Treating Patients with Advanced Lung Cancer vol.16, pp.9, 2015, https://doi.org/10.7314/APJCP.2015.16.9.4003
  14. Clinical Application of Recombinant Human Endostatin in Postoperative Early Complementary Therapy on Patients with Non-small Cell Lung Cancer in Chinese Mainland vol.16, pp.9, 2015, https://doi.org/10.7314/APJCP.2015.16.9.4013
  15. Targeting cancer with sesterterpenoids: the new potential antitumor drugs vol.69, pp.3, 2015, https://doi.org/10.1007/s11418-015-0911-y
  16. Safety and Efficacy of a Mouth-Rinse with Granulocyte Colony Stimulating Factor in Patients with Chemotherapy-Induced Oral Mucositis vol.17, pp.1, 2016, https://doi.org/10.7314/APJCP.2016.17.1.413
  17. A Clinical Study on Juheli (Recombinant Human Interleukin - 11) in the Second Prevention of Chemotherapy Induced Thrombocytopenia vol.17, pp.2, 2016, https://doi.org/10.7314/APJCP.2016.17.2.485
  18. The safety and clinical efficacy of recombinant human granulocyte colony stimulating factor injection for colon cancer patients undergoing chemotherapy vol.63, pp.12, 2017, https://doi.org/10.1590/1806-9282.63.12.1061